CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Zydus receive tentative USFDA approval for Macitentan tablets
DSIJ Intelligence
/ Categories: Trending, DSIJ News

Zydus receive tentative USFDA approval for Macitentan tablets

On Wednesday, Zydus Worldwide DMCC, a wholly-owned subsidiary of Cadila Healthcare Limited, announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) to market Macitentan tablets (US RLD: Opsumit tablets), 10 mg.

The medication indicated is used for the treatment of pulmonary arterial hypertension. The drug will be manufactured at CMO Umedica Laboratories Pvt Ltd, Vapi (Gujarat). The group stated that it has now 287 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare Limited manufactures and markets healthcare solutions ranging from formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. Its products are available in tablets, capsules, injections, liquids, dry syrups, powders, granules and ointments.

On Wednesday, the stock closed at Rs 339.05, down by 4.13 per cent or Rs 14.60 per share. The 52-week high is recorded at Rs 378 and the 52-week low is Rs 206.45 on BSE.

Previous Article Moodys to review JSW Steel rating for downgrade
Next Article Acrysil resumes partial operation at Gujarat factory amid lockdown
Print
844 Rate this article:
3.7
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR